Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fluticasone propionate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    292 result(s) found for: Fluticasone propionate. Displaying page 9 of 15.
    EudraCT Number: 2007-000135-26 Sponsor Protocol Number: 2006-04-DOS-2 Start Date*: 2007-06-08
    Sponsor Name:Hexal AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50...
    Medical condition: Persistent, moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001532-19 Sponsor Protocol Number: 206821 Start Date*: 2018-09-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised open-label study to compare the effectiveness of the fixed dose combination of FF/UMEC/VI (using the Connected Inhaler System) with the combination of FP/SAL plus tiotropium (without t...
    Medical condition: Inadequately controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020144-34 Sponsor Protocol Number: FFA112059 Start Date*: 2010-09-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: FFA112059: A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in t...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023169-23 Sponsor Protocol Number: 1248.7 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double-blind, double-dummy, active-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 90.9 181.8 and 363.6 μg ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Prematurely Ended) FR (Ongoing) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004162-17 Sponsor Protocol Number: FLT3509 Start Date*: 2013-10-24
    Sponsor Name:Mundipharma Research Limited
    Full Title: A randomised, double-blind, double dummy, parallel group study comparing Fluticasone propionate / formoterol fumarate (flutiform®) 250/10 μg (2 puffs BID) and flutiform® 125/5 μg (2 puffs BID) vers...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) LV (Completed) LT (Completed) BG (Completed) ES (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014551-80 Sponsor Protocol Number: 1268.16 Start Date*: 2010-01-21
    Sponsor Name:BOEHRINGER ING.
    Full Title: Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placeb...
    Medical condition: patients with symptomatic asthma on inhaled corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000648-86 Sponsor Protocol Number: OPN-FLU-CS-3206 Start Date*: 2019-10-01
    Sponsor Name:OptiNose US, Inc.
    Full Title: A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (B...
    Medical condition: Chronic rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) ES (Ongoing) BG (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-023621-37 Sponsor Protocol Number: CQVA149A2313 Start Date*: 2011-02-23
    Sponsor Name:Novartis Farmacéutica S. A
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento, de grupos paralelos, de 26 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de QVA149 en compa...
    Medical condition: EPOC
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) HU (Completed) BE (Completed) LT (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-003740-11 Sponsor Protocol Number: CCD-0806-PR-0032 Start Date*: 2009-01-23
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Estudio Fase IV, multinacional, multicéntrico, doble ciego, doble simulación, randomizado, de grupos paralelos, controlado, sobre la combinación de dosis fijas de Dipropionato de Beclometasona 100 ...
    Medical condition: Asma Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004442-32 Sponsor Protocol Number: FFA109687 Start Date*: 2008-02-21
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Flutic...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) EE (Completed) PL (Ongoing) SK (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001386-34 Sponsor Protocol Number: BY9010/M1-208 Start Date*: 2005-06-23
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of Ciclesonide (320 µg/day) vs. Fluticasone Propionate (375 µg/day) vs. Placebo on Short-term Linear Growth Rate and HPA-axis Function in Prepubertal Children with Mild Asthma A double-bl...
    Medical condition: asthma bronchiale
    Disease: Version SOC Term Classification Code Term Level
    5.1 10003553 llt
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000134-39 Sponsor Protocol Number: 2006-03-DOS-1 Start Date*: 2007-04-19
    Sponsor Name:Hexal AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/125 µg per actuation) versus SeretideTM 1...
    Medical condition: persistent moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-001304-37 Sponsor Protocol Number: 205715 Start Date*: 2016-11-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual co...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020177-16 Sponsor Protocol Number: CQAW039A2201 Start Date*: 2011-01-28
    Sponsor Name:NOVARTIS PHARMA SERVICES AG
    Full Title: A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma
    Medical condition: Mild to moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) BG (Prematurely Ended) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004632-30 Sponsor Protocol Number: BDB-AS-302 Start Date*: 2015-05-16
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered ...
    Medical condition: Persistent Asthma
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001841-40 Sponsor Protocol Number: GW685698X Start Date*: 2005-10-05
    Sponsor Name:GlaxoSmithKline Research And Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg Twice-Daily, GW685698X Inhalation Powder ...
    Medical condition: Persistent asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001521-27 Sponsor Protocol Number: SP-1011-003 Start Date*: 2020-08-03
    Sponsor Name:Adare Pharmaceuticals US, LP
    Full Title: Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects w...
    Medical condition: Eosinophilic Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001540-56 Sponsor Protocol Number: 208657 Start Date*: 2019-08-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005349-13 Sponsor Protocol Number: MC/PR/033011/005/06 Start Date*: 2007-03-27
    Sponsor Name:CHIESI
    Full Title: PROSPECTIVE, RANDOMIZED, OPEN-LABEL, MULTICENTRE,ACTIVE DRUG CONTROLLED, PARALLEL GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE 400 MCG FORMOTEROL 24 MCG ...
    Medical condition: ASTHMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021858-20 Sponsor Protocol Number: PPH/00071/10 Start Date*: Information not available in EudraCT
    Sponsor Name:PALAU PHARMA, S.A.
    Full Title: DOUBLE BLIND RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PROOF OF ACTIVITY STUDY OF UR-63325 IN ALLERGIC RHINITIS INDUCED BY NASAL CHALLENGE TO ALLERGIC PATIENTS OTHERWISE HEALTHY.
    Medical condition: Male subjects with seasonal allergic rhinitis to grass but otherwise healthy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 02:36:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA